Ciraparantag

DRUG3 trials

Sponsors

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc.

Conditions

Healthy

Phase 2

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

CompletedNCT03172910

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Healthy

Start: 2017-05-08End: 2019-11-12Updated: 2025-09-02

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

CompletedNCT03288454

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Healthy

Start: 2017-08-30End: 2019-08-05Updated: 2025-09-02

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

TerminatedNCT04593784

AMAG Pharmaceuticals, Inc.Healthy

Start: 2021-10-13End: 2023-08-26Updated: 2026-04-20